1. Home
  2. SOWG vs EVAX Comparison

SOWG vs EVAX Comparison

Compare SOWG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$3.55

Market Cap

25.4M

ML Signal

HOLD

Logo Evaxion Biotech

EVAX

Evaxion Biotech

HOLD

Current Price

$3.17

Market Cap

25.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
EVAX
Founded
2010
2008
Country
United States
Denmark
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
25.8M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
SOWG
EVAX
Price
$3.55
$3.17
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$11.67
AVG Volume (30 Days)
143.2K
24.3K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$2.45
52 Week High
$4.45
$12.15

Technical Indicators

Market Signals
Indicator
SOWG
EVAX
Relative Strength Index (RSI) 60.04 40.93
Support Level $0.51 $2.97
Resistance Level $4.43 $3.62
Average True Range (ATR) 0.64 0.25
MACD -0.02 0.02
Stochastic Oscillator 65.37 24.88

Price Performance

Historical Comparison
SOWG
EVAX

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: